Baird analyst Joel Beatty lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $47.00 (from $72.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE